Boys Archives - PharmaLive

FDA Grants Fast Track Designation to Pfizer’s DMD Gene Therapy

Boys, Business, Clinical Trial Endpoints, Clinical Trials, Duchenne Muscular Dystrophy (DMD), Fast Track Designation, FDA/Regulatory, Gene Therapy, Muscle strength, R&D

Pfizer snagged Fast Track designation from the U.S. Food and Drug Administration for the company’s Duchenne muscular dystrophy (DMD) gene therapy treatment, PF-06939926.

CRISPR-Based Gene Therapy for Duchenne Muscular Dystrophy Shows Promise

Boys, Duchenne Muscular Dystophy (DMD), Gene Therapy, Human Dystrophin Gene, Muscle Wasting Disorders, Mutations, Nature Medicine, R&D

Researchers at Technical University of Munich (TUM) recently developed a gene therapy that might cure Duchenne muscular dystrophy.

Roche Terminates Myostatin Inhibitor for DMD

Boys, Children, Clinical Trials, Duchenne Muscular Dystrophy (DMD), Monoclonal Antibodies, Myostatin Inhibitors, R&D, Terminated Development

A little more than one year after Pfizer terminated the company’s studies of PF-06252616 as a potential treatment for Duchenne muscular dystrophy, Swiss pharma giant Roche is following suit with the terminated development of RG6206.